U.S. drafts new investment rules to keep pharma licensing deals with China viable

The United States is drafting new guidelines that would govern how American investors can fund Chinese biotech and pharmaceutical companies. The proposed framework is intended to address national‑security concerns while preserving the flow of cross‑border licensing agreements.

According to the draft, most licensing transactions would remain permissible under the new rules, with only high‑risk deals subject to additional review. Officials say the approach aims to avoid a blanket ban that could disrupt drug development pipelines.

Industry analysts view the move as a positive signal for companies that rely on Chinese innovations to supplement their pipelines. By keeping licensing channels open, the rules could help maintain access to novel compounds and technologies.

The column also notes other emerging topics, such as experiments with manufacturing drugs in space and AI‑driven biology labs, but the primary focus is on the regulatory steps that could shape future pharma collaborations with China.